Sun Pharmaceutical Industries Limited announced that it has acquired three brands viz. Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg &RutosideTrihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg &RutosideTrihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg &RutosideTrihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”), a Mumbai based research driven healthcare entity with more than two decades of experience in the healthcare field.

.  All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.

All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.

Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013.

KirtiGanorkar, CEO-India business, Sun Pharma, said, “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds-up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation.”